Alnylam Pharmaceuticalsvs.Vertex Pharmaceuticals
ALNY vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 4.5× larger than Alnylam Pharmaceuticals by market cap; Vertex Pharmaceuticals trades at the lower P/E (30.7 vs 37.6); year to date, Vertex Pharmaceuticals leads (+20.8% vs −40.6%).
Side by side
| ALNY | VRTX | |
|---|---|---|
| Market cap | $30.4B | $135B |
| Price | $240.08 | $552.85 |
| Today | +1.7% | +1.0% |
| Return YTD | −40.6% | +20.8% |
| Return 1Y | −48.1% | +38.6% |
| P/E | 37.6 | 30.7 |
| P/S | 6.3 | 10.7 |
| P/B | 22.4 | 6.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More ALNY & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where ALNY and VRTX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →